Investigational Drug Information for SRX246
✉ Email this page to a colleague
What is the development status for investigational drug SRX246?
SRX246 is an investigational drug.
There have been 7 clinical trials for SRX246.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Anxiety Disorders, Huntington Disease, and Disruptive, Impulse Control, and Conduct Disorders. The leading clinical trial sponsors are Azevan Pharmaceuticals, National Institute of Mental Health (NIMH), and National Institute of Neurological Disorders and Stroke (NINDS).
There is one US patent protecting this investigational drug and sixty-two international patents.
Summary for SRX246
| US Patents | 1 |
| International Patents | 62 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2016-12-01) |
| Vendors | 22 |
Recent Clinical Trials for SRX246
| Title | Sponsor | Phase |
|---|---|---|
| Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans | National Institute of Mental Health (NIMH) | Phase 1 |
| Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans | Azevan Pharmaceuticals | Phase 1 |
| Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans | National Institute of Mental Health (NIMH) | Phase 1 |
Clinical Trial Summary for SRX246
Top disease conditions for SRX246
Top clinical trial sponsors for SRX246
US Patents for SRX246
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SRX246 | ⤷ Subscribe | Use of arginine vasopressin receptor antagonists for the treatment of prostate cancer | UNIVERSITY OF MIAMI (Miami, FL) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SRX246
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SRX246 | Australia | AU2011272738 | 2030-07-01 | ⤷ Subscribe |
| SRX246 | Australia | AU2015258200 | 2030-07-01 | ⤷ Subscribe |
| SRX246 | Canada | CA2804001 | 2030-07-01 | ⤷ Subscribe |
| SRX246 | China | CN103269584 | 2030-07-01 | ⤷ Subscribe |
| SRX246 | China | CN107007596 | 2030-07-01 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
